{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:05:10Z","timestamp":1789477510696,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Homologous recombination (HR) deficiency (HRD) from germline\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of\n                      <jats:italic>BRCA1<\/jats:italic>\n                      (me\n                      <jats:italic>BRCA1<\/jats:italic>\n                      ) or\n                      <jats:italic>RAD51C<\/jats:italic>\n                      (me\n                      <jats:italic>RAD51C<\/jats:italic>\n                      ) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Single-arm phase 2 trial of olaparib 300\u2009mg orally twice daily. Tumour me\n                      <jats:italic>BRCA1\/<\/jats:italic>\n                      me\n                      <jats:italic>RAD51C<\/jats:italic>\n                      determined by methylation-sensitive, high-resolution melting PCR and targeted sequencing. Unmethylated cases underwent HR gene mutation testing. Primary outcome: objective tumour response rate (OTRR) at 6 months(m). Secondary outcomes: progression-free survival (PFS), OTRR according to HR gene aberration, and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Total 22 enrolled: promoter methylation detected in 8\/15 HGSOC and 5\/7 TNBC, and pathogenic variants (PV) in non-\n                      <jats:italic>BRCA<\/jats:italic>\n                      HR genes. OTRR at 6\u2009m was 40% HGSOC and 0% TNBC. OTRR was 38% in methylated cases vs 43% for other HRD. 6\u2009m\/12\u2009m PFS were 53% \/ 25% (HGSOC), and 17% \/ 0% (TNBC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Olaparib demonstrated activity in HGSOC beyond gBRCAm, including with me\n                      <jats:italic>BRCA1<\/jats:italic>\n                      or\n                      <jats:italic>gRAD51C<\/jats:italic>\n                      PV. Olaparib had limited activity in pre-treated TNBC. Effects of prior chemotherapy on me\n                      <jats:italic>BRCA1\/<\/jats:italic>\n                      me\n                      <jats:italic>RAD51C<\/jats:italic>\n                      require exploration to improve patient selection for PARPi.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registration<\/jats:title>\n                    <jats:p>Australian New Zealand Clinical Trials Registry Registration number ACTRN 12617000855325.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03535-6","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:27:58Z","timestamp":1783520878000},"page":"1152-1163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1\/2: phase 2 EMBRACE trial"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-8682","authenticated-orcid":false,"given":"Katrin M.","family":"Sjoquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dobrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy P.","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Nesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-1458","authenticated-orcid":false,"given":"Sally","family":"Baron-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumitra","family":"Ananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Steer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-6014","authenticated-orcid":false,"given":"Linda R.","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Lynn","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-3722","authenticated-orcid":false,"given":"Danka S.","family":"Zebic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-8607","authenticated-orcid":false,"given":"U. G. Imalki U.","family":"Kariyawasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3969-9846","authenticated-orcid":false,"given":"Kristy","family":"Shield-Artin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jarratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-0212","authenticated-orcid":false,"given":"Justin","family":"Bed\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Papenfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-5149","authenticated-orcid":false,"given":"Olga","family":"Kondrashova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4698","authenticated-orcid":false,"given":"Matthew J.","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-8873","authenticated-orcid":false,"given":"Cassandra J.","family":"Vandenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-8724","authenticated-orcid":false,"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Waring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"3535_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"3535_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"3535_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2147\/OTT.S272199","volume":"15","author":"RE Miller","year":"2022","unstructured":"Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA. Ovarian cancer therapy: homologous recombination deficiency as a predictive biomarker of response to PARP inhibitors. Onco Targets Ther. 2022;15:1105\u201317.","journal-title":"Onco Targets Ther"},{"key":"3535_CR4","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"3535_CR5","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31:1606\u201322.","journal-title":"Ann Oncol"},{"key":"3535_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"3535_CR7","first-page":"31","volume":"61","author":"TA Yap","year":"2011","unstructured":"Yap TA, Sandhu SK, Carden CP, De Bono JS. Poly(ADP-Ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA: A Cancer J Clin. 2011;61:31\u201349.","journal-title":"CA: A Cancer J Clin"},{"key":"3535_CR8","doi-asserted-by":"crossref","unstructured":"Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, et al. Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer. 2021;21:1154.","DOI":"10.1186\/s12885-021-08863-9"},{"key":"3535_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clbc.2021.12.007","volume":"22","author":"EM Walsh","year":"2022","unstructured":"Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, et al. Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1\/2 mutations or mutations in non-BRCA1\/2, DNA damage repair genes. Clin Breast Cancer. 2022;22:319\u201325.","journal-title":"Clin Breast Cancer"},{"key":"3535_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764\u201375.","journal-title":"Clin Cancer Res"},{"key":"3535_CR11","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/cncr.33517","volume":"127","author":"CK Lee","year":"2021","unstructured":"Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, et al. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: a meta-analysis. Cancer. 2021;127:2432\u201341.","journal-title":"Cancer"},{"key":"3535_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"FJ Couch","year":"2015","unstructured":"Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 Breast Cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304\u201311.","journal-title":"J Clin Oncol"},{"key":"3535_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00258","volume":"7","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, et al. Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1\/ENGOT-ov25 trial. JCO Precis Oncol. 2023;7:e2200258.","journal-title":"JCO Precis Oncol"},{"key":"3535_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ygyno.2011.12.415","volume":"124","author":"KP Pennington","year":"2012","unstructured":"Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol. 2012;124:347\u201353.","journal-title":"Gynecol Oncol"},{"key":"3535_CR15","first-page":"3347","volume":"57","author":"A Dobrovic","year":"1997","unstructured":"Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997;57:3347\u201350.","journal-title":"Cancer Res"},{"key":"3535_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/carcin\/21.2.147","volume":"21","author":"T Bianco","year":"2000","unstructured":"Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis. 2000;21:147\u201351.","journal-title":"Carcinogenesis"},{"key":"3535_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00280-014-2404-1","volume":"73","author":"M Foedermayr","year":"2014","unstructured":"Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, et al. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2014;73:771\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3535_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-523","volume":"13","author":"W Jacot","year":"2013","unstructured":"Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne A-C, Lopez-Crapez E, et al. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer. 2013;13:523.","journal-title":"BMC Cancer"},{"key":"3535_CR19","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.ejca.2014.05.001","volume":"50","author":"I Ruscito","year":"2014","unstructured":"Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients-a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). Eur J Cancer. 2014;50:2090\u20138.","journal-title":"Eur J Cancer"},{"key":"3535_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1940-6207.CAPR-10-0212","volume":"4","author":"EM Wong","year":"2011","unstructured":"Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, et al. Constitutional Methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res. 2011;4:23\u201333.","journal-title":"Cancer Prev Res"},{"key":"3535_CR21","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/jnci\/djaa070","volume":"112","author":"RD Kalachand","year":"2020","unstructured":"Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, et al. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2020;112:1190\u2013203.","journal-title":"J Natl Cancer Inst"},{"key":"3535_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ygyno.2019.02.011","volume":"153","author":"CB Morse","year":"2019","unstructured":"Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, et al. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecol Oncol. 2019;153:217\u201322.","journal-title":"Gynecol Oncol"},{"key":"3535_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2217\/epi.10.32","volume":"2","author":"T Mikeska","year":"2010","unstructured":"Mikeska T, Candiloro IL, Dobrovic A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics. 2010;2:561\u201373.","journal-title":"Epigenomics"},{"key":"3535_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1868-7083-6-22","volume":"6","author":"AM Lim","year":"2014","unstructured":"Lim AM, Candiloro ILM, Wong N, Collins M, Do H, Takano EA, et al. Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. Clin Epigenet. 2014;6:22.","journal-title":"Clin Epigenet"},{"key":"3535_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E, Ho G-Y, Harrell MI, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9:3970.","journal-title":"Nat Commun"},{"key":"3535_CR26","doi-asserted-by":"crossref","unstructured":"Xu L, Liddell B, Nesic K, Geissler F, Ashwood LM, Wakefield MJ, et al. High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers. NAR Cancer. 2024;6.","DOI":"10.1093\/narcan\/zcae033"},{"key":"3535_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","volume":"7","author":"O Kondrashova","year":"2017","unstructured":"Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP Inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7:984\u201398.","journal-title":"Cancer Discov"},{"key":"3535_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"A-M Patch","year":"2015","unstructured":"Patch A-M, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole\u2013genome characterization of chemoresistant ovarian cancer. Nature. 2015;521:489\u201394.","journal-title":"Nature"},{"key":"3535_CR29","doi-asserted-by":"crossref","unstructured":"Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021;12:2487.","DOI":"10.1038\/s41467-021-22582-6"},{"key":"3535_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1926","volume":"14","author":"F Menghi","year":"2022","unstructured":"Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, et al. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. Sci Transl Med. 2022;14:eabn1926.","journal-title":"Sci Transl Med"},{"key":"3535_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32:240\u20139.","journal-title":"Ann Oncol"},{"key":"3535_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10549-020-05647-w","volume":"181","author":"A Kawachi","year":"2020","unstructured":"Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, et al. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib\/eribulin combination therapy. Breast Cancer Res Treat. 2020;181:323\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"3535_CR33","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-21-0774","volume":"81","author":"K Nesic","year":"2021","unstructured":"Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho G-Y, et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma. Cancer Res. 2021;81:4709\u201322.","journal-title":"Cancer Res"},{"key":"3535_CR34","doi-asserted-by":"crossref","unstructured":"Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel Taylor M, Kelly Rebecca L, et al. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer. 2021;3:zcab028.","DOI":"10.1093\/narcan\/zcab028"},{"key":"3535_CR35","doi-asserted-by":"publisher","first-page":"e1006853","DOI":"10.1371\/journal.pgen.1006853","volume":"13","author":"M Kawazu","year":"2017","unstructured":"Kawazu M, Kojima S, Ueno T, Totoki Y, Nakamura H, Kunita A, et al. Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency. PLoS Genet. 2017;13:e1006853.","journal-title":"PLoS Genet"},{"key":"3535_CR36","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","volume":"11","author":"P Aftimos","year":"2021","unstructured":"Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, et al. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov. 2021;11:2796\u2013811.","journal-title":"Cancer Discov"},{"key":"3535_CR37","doi-asserted-by":"crossref","unstructured":"Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, et al. Exquisitely platinum-sensitive triple-negative breast cancer, time for BRCA methylation testing? JCO Prec Oncol. 2022;6:e2200309.","DOI":"10.1200\/PO.22.00309"},{"key":"3535_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jnci\/djq509","volume":"103","author":"Y Drew","year":"2011","unstructured":"Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103:334\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"3535_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma\u00f1a J, et al. Olaparib monotherapy in patients with advanced cancer and a Germline BRCA1\/2 mutation. J Clin Oncol. 2015;33:244\u201350.","journal-title":"J Clin Oncol"},{"key":"3535_CR40","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.coph.2005.03.006","volume":"5","author":"N Turner","year":"2005","unstructured":"Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharm. 2005;5:388\u201393.","journal-title":"Curr Opin Pharm"},{"key":"3535_CR41","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1200\/JCO.2010.30.1010","volume":"28","author":"J Veeck","year":"2010","unstructured":"Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, et al. BRCA1 CpG Island hypermethylation predicts sensitivity to Poly(Adenosine Diphosphate)- ribose polymerase inhibitors. J Clin Oncol. 2010;28:e563\u2013e4.","journal-title":"J Clin Oncol"},{"key":"3535_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jmoldx.2024.11.004","volume":"27","author":"JL Fink","year":"2025","unstructured":"Fink JL, Jaradi B, Stone N, Sanker B, Zhang F, Dobrovic A, et al. Validation and performance of quantitative BRCA1 and RAD51C promoter hypermethylation testing in breast and ovarian cancers. J Mol Diagn. 2025;27:139\u201353.","journal-title":"J Mol Diagn"},{"key":"3535_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. nature. 2013;500:415\u201321.","journal-title":"nature"},{"key":"3535_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16:475.","journal-title":"Breast Cancer Res"},{"key":"3535_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101638","volume":"31","author":"O Pitiyarachchi","year":"2023","unstructured":"Pitiyarachchi O, Lee YC, Sim H-W, Srirangan S, Mapagu C, Kirk J, et al. Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. Transl Oncol. 2023;31:101638.","journal-title":"Transl Oncol"},{"key":"3535_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1586\/erm.10.46","volume":"10","author":"TK Wojdacz","year":"2010","unstructured":"Wojdacz TK, M\u00f8ller TH, Thestrup BB, Kristensen LS, Hansen LL. Limitations and advantages of MS-HRM and bisulfite sequencing for single locus methylation studies. Expert Rev Mol Diagn. 2010;10:575\u201380.","journal-title":"Expert Rev Mol Diagn"},{"key":"3535_CR47","doi-asserted-by":"crossref","unstructured":"Wong EM, Dobrovic A. Assessing gene-specific methylation using HRM-based analysis. In: Park D, ed. PCR Protocols. Method in Molecular Biology, 2011;687:207\u201317.","DOI":"10.1007\/978-1-60761-944-4_14"},{"key":"3535_CR48","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/nprot.2008.191","volume":"3","author":"TK Wojdacz","year":"2008","unstructured":"Wojdacz TK, Dobrovic A, Hansen LL. Methylation-sensitive high-resolution melting. Nat Protoc. 2008;3:1903\u20138.","journal-title":"Nat Protoc"},{"key":"3535_CR49","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1158\/1078-0432.CCR-23-2513","volume":"30","author":"TJ Tan","year":"2024","unstructured":"Tan TJ, Sammons S, Im Y-H, She L, Mundy K, Bigelow R, et al. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2024;30:1240\u20137.","journal-title":"Clin Cancer Res"},{"key":"3535_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64130-6","volume":"16","author":"CK Lee","year":"2025","unstructured":"Lee CK, Kartikasari AER, Bound NT, Francis KE, Shield-Artin K, Bedo J, et al. Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial. Nat Commun. 2025;16:9756.","journal-title":"Nat Commun"},{"key":"3535_CR51","unstructured":"GCIG: Gynecologic Cancer Intergroup. GCIG CA 125 Response Definition 2005. Available from: http:\/\/www.gcig.igcs.org\/CA125\/respdef_nov2005.pdf. Accessed Dec 2015."},{"key":"3535_CR52","unstructured":"Team RC. R: A language and environment for statistical computing. Vienna, Austria. : R Foundation for Statistical Computing; 2023."},{"key":"3535_CR53","doi-asserted-by":"publisher","first-page":"662","DOI":"10.20517\/cdr.2022.12","volume":"5","author":"S-F Ngu","year":"2022","unstructured":"Ngu S-F, Ngan HY, Chan KK. A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report. Cancer Drug Resistance. 2022;5:662.","journal-title":"Cancer Drug Resistance"},{"key":"3535_CR54","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.annonc.2020.03.283","volume":"31","author":"T Grellety","year":"2020","unstructured":"Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, et al. Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. Ann Oncol. 2020;31:822\u20133.","journal-title":"Ann Oncol"},{"key":"3535_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ygyno.2023.11.019","volume":"180","author":"RM Kahn","year":"2024","unstructured":"Kahn RM, Selenica P, Boerner T, Roche KL, Xiao Y, Sia TY, et al. Pathogenic germline variants in non-BRCA1\/2 homologous recombination genes in ovarian cancer: analysis of tumor phenotype and survival. Gynecologic Oncol. 2024;180:35\u201343.","journal-title":"Gynecologic Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03535-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03535-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03535-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:13:55Z","timestamp":1789474435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03535-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,5]]}},"alternative-id":["3535"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03535-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KM Sjoquist reports research support to institution from Bayer Pharmaceuticals and Lisata Therapuetics outside the submitted work. KM Sjoquist reports advisory boards: BMS, Servier, MSD, Astellas, Merck. Consulting fees to institution for IDSMC membership: Novotech. C. Steer reports receiving honoraria for advisory board membership from GSK, Ipsen, Janssen, MSD and Sanofi and speaker fees from Astra Zeneca, BMS, Eisai, Novartis and Roche. LR Mileshkin reports uncompensated speaking at educational events, and uncompensated advisory board participation for Astra Zeneca. JL Fink has received consulting fees and conference travel support from Pillar Biosciences. K Shield-Artin, K. Nesic, MJ Wakefield, CJ Vandenberg and C.L. Scott report research support (paid to institution) from AstraZeneca Pty Ltd, Boehringer Ingelheim and IDEAYA Biosciences outside the submitted work. O. Kondrashova has received consulting fees from Xing Genomic Services and has received travel honorarium from AstraZeneca. MR Stockler reports research support to institution from Amgen, Astellas, Astra Zeneca, Bayer, Beigene, BMS, MSD, Novartis, Pfizer, Roche, and Tilray. CL Scott reports unpaid advisory boards: AstraZeneca Pty Ltd., Clovis Oncology, Roche, Eisai, Sierra Oncology, Takeda, MSD, research grants from AstraZeneca Pty Ltd., Eisai, Sierra Oncology, Ideaya and Boehringer Ingelheim, and travel support from AstraZeneca, Roche, MSD and Takeda. P. Waring is a SAB member and shareholder in Pillar Biosciences and was an employee of Astra Zeneca, from May 2020 to July 2024 during which he continued to oversee the pre-screening program but was not involved in the conduct or analysis of the trial during this period. The other authors report no conflicts.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All participants provided written informed consent prior to study procedures. The protocol and all amendments were approved by the Sydney Local Health District Human Research Ethics Committee and local institutions in all participating centres. Australian New Zealand Clinical Trials Registry Registration number ACTRN 12617000855325.","order":2,"name":"Ethics","label":"Ethics and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}